FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
pemigatinib + TP-0903 Sensitive: D – Preclinical
|
pemigatinib + TP-0903 Sensitive: D – Preclinical
|
FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
pemigatinib + BGB324 Sensitive: D – Preclinical
|
pemigatinib + BGB324 Sensitive: D – Preclinical
|
FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
TP-0903 Sensitive: D – Preclinical
|
TP-0903 Sensitive: D – Preclinical
|
FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
BGB324 Sensitive: D – Preclinical
|
BGB324 Sensitive: D – Preclinical
|
FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
FGFR2-AFF4 fusion
|
Cholangiocarcinoma
|
pemigatinib Resistant: D – Preclinical
|
pemigatinib Resistant: D – Preclinical
|